- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
MPNs | Clinical
Miller Discusses the REVEAL Trial for Polycythemia Vera
November 25, 2021
Carole Miller, MD, discusses the REVEAL trial design, an observational study on mortality and causes of death in patients with polycythemia vera.
The Expanding Role of Interferons in Myeloproliferative Neoplasms
November 24, 2021
In an interview with Targeted Oncology™, Richard T. Silver, MD, discussed the role of interferon in the treatment of myeloproliferative neoplasm as well as the importance of the 3-year global MPN initiative being conducted by the MPN Research Foundation.
Study of Ruxolitinib Pre and Post HSCT for Myelofibrosis Currently Recruiting
November 22, 2021
The study is currently recruiting in 5 states and aims to determine if ruxolitinib affects GvHD rates in patients received HSCT for the treatment of myelofibrosis.
FDA Approves Ropeginterferon Alfa-2b-njft for Adults With Polcythemia Vera
November 13, 2021
Ropeginterferon alfa-2b-njft has been granted FDA approval for the treatment of adults patients with polycythemia vera.
Treating Post-MPN Acute Leukemia Remains an Unmet Medical Need
October 18, 2021
In an interview with Targeted Oncology, Gabriela Hobbs, MD discussed the current treatment landscape for MPNs and the research that is aiming to address post-MPN acute leukemia and unmet needs for the patient population.
Integrating Prognostic Risk Score into the Diagnosis and Treatment of Patients With MPNs
October 15, 2021
During the NCCN 2021 Congress: Hematologic Malignancies, Aaron T. Gerds, MD, MS, explained the risk stratification tools used in patients with myeloproliferative neoplasms.
Unmet Needs Loom for Later-Line Options in MPNs
October 13, 2021
Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses the need for new drugs after patients with myelofibrosis are treated with JAK inhibitors.
Tipifarnib May Be Effective and Safe in Select Patients with CMML, MDS, or MPNs
October 04, 2021
A phase 2 study suggests that tipifarnib may be more beneficial for patients with CMML, MDS, or MPNs and RAS pathway mutations than the general population of patients with these disease.
Ali Discusses Treatment Options and Spleen Size in Primary Myelofibrosis
September 30, 2021
Haris Ali, MD, discussed a 68-year-old woman who presented to her physician with symptoms of fatigue and abdominal pain lasting 4 months; she also reported increased bruising.
Unmet Clinical Needs in Myelofibrosis
September 28, 2021
Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses unmet clinical needs in myelofibrosis.